176 related articles for article (PubMed ID: 20360719)
1. Counterpoint: Data first.
Golub T
Nature; 2010 Apr; 464(7289):679. PubMed ID: 20360719
[No Abstract] [Full Text] [Related]
2. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Carella AM
Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
[No Abstract] [Full Text] [Related]
3. Roots of clinical resistance to STI-571 cancer therapy.
Hochhaus A; Kreil S; Corbin A; La Rosée P; Lahaye T; Berger U; Cross NC; Linkesch W; Druker BJ; Hehlmann R; Gambacorti- Passerini C; Corneo G; D'Incalci M
Science; 2001 Sep; 293(5538):2163. PubMed ID: 11569495
[No Abstract] [Full Text] [Related]
4. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Agarwal MB
J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
[No Abstract] [Full Text] [Related]
5. Chronic myelogenous leukemia. Preface.
DeAngelo DJ
Hematol Oncol Clin North Am; 2011 Oct; 25(5):ix-x. PubMed ID: 22054737
[No Abstract] [Full Text] [Related]
6. Cancer biology: summing up cancer stem cells.
Huntly BJ; Gilliland DG
Nature; 2005 Jun; 435(7046):1169-70. PubMed ID: 15988505
[No Abstract] [Full Text] [Related]
7. [STI571: the resistance organizes!].
Jeanteur P
Bull Cancer; 2001 Sep; 88(9):819. PubMed ID: 11642306
[No Abstract] [Full Text] [Related]
8. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Drummond MW; Holyoake TL
Cancer; 2003 Oct; 98(8):1776-7; author reply 1777-8. PubMed ID: 14534900
[No Abstract] [Full Text] [Related]
9. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
Laneuville P; Dilea C; Yin OQ; Woodman RC; Mestan J; Manley PW
J Clin Oncol; 2010 Apr; 28(11):e169-71; author reply e172. PubMed ID: 20194843
[No Abstract] [Full Text] [Related]
10. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
Druker BJ
Oncogene; 2002 Dec; 21(56):8541-6. PubMed ID: 12476300
[No Abstract] [Full Text] [Related]
11. Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance.
Travis J
Science; 2004 Jul; 305(5682):319-21. PubMed ID: 15256643
[No Abstract] [Full Text] [Related]
12. Roots of clinical resistance to STI-571 cancer therapy.
Barthe C; Cony-Makhoul P; Melo JV; Mahon JR
Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109
[No Abstract] [Full Text] [Related]
13. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.
Caocci G; Atzeni S; Orrù N; Littera R; Culurgioni F; Marongiu F; La Nasa G
Leuk Res; 2010 Jan; 34(1):e27-9. PubMed ID: 19748671
[No Abstract] [Full Text] [Related]
14. Cancer research. Why some leukemia cells resist STI-571.
Marx J
Science; 2001 Jun; 292(5525):2231-3. PubMed ID: 11423629
[No Abstract] [Full Text] [Related]
15. Exploiting oxidative damage to overcome resistance.
Karp JE; Smith BD
Leuk Res; 2006 Oct; 30(10):1213-4. PubMed ID: 16564572
[No Abstract] [Full Text] [Related]
16. [Chronic myeloid leukemia as a model for the development and therapeutic use of tyrosine kinase inhibitors].
López-Karpovitch X
Rev Invest Clin; 2003; 55(2):191-5. PubMed ID: 12827926
[No Abstract] [Full Text] [Related]
17. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
Snyder DS; McMahon R; Cohen SR; Slovak ML
Am J Hematol; 2004 Feb; 75(2):92-5. PubMed ID: 14755375
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
19. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib.
Kang HY; Hwang JY; Kim SH; Goh HG; Kim M; Kim DW
Haematologica; 2006 May; 91(5):659-62. PubMed ID: 16627254
[TBL] [Abstract][Full Text] [Related]
20. Imatinib as a paradigm of targeted therapies.
Druker BJ
Adv Cancer Res; 2004; 91():1-30. PubMed ID: 15327887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]